Blackstone Inc (BBN1.BE)
| Previous close | 121.00 |
| Open | 117.22 |
| Bid | 115.42 x N/A |
| Ask | 115.74 x N/A |
| Day's range | 117.22 - 117.22 |
| 52-week range | 76.40 - 121.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Blackstone to Acquire Majority Stake in Priority Software
TEL AVIV, Israel, May 16, 2024--Blackstone today announced that Blackstone Growth and affiliated funds (collectively "Blackstone") have entered into a definitive agreement to acquire a majority stake in Priority Software, a leading provider of mission-critical business software. Blackstone’s investment will help build on the company’s position at the forefront of the ERP software market and support its further growth across industries and markets.
- Business Wire
Blackstone to Present at Bernstein’s 40th Annual Strategic Decisions Conference
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) announced today that Jon Gray, President and Chief Operating Officer, is scheduled to present at Bernstein’s 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 at 10:00am ET.
- Business Wire
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences ("Blackstone") portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug ("IND") application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indicatio
